CIP
CSTL icon

Chartwell Investment Partners’s Castle Biosciences CSTL Stock Holding History

Chartwell Investment Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,508
Closed -$651K – 419
2022
Q1 		$651K Buy
14,508
+607
+4% +$25.1K 0.02% 397
2021
Q4 		$596K Sell
13,901
-245
-2% -$12.8K 0.02% 405
2021
Q3 		$941K Hold
14,146
– – 0.03% 382
2021
Q2 		$1.04M Buy
14,146
+127
+0.9% +$8.39K 0.03% 371
2021
Q1 		$960K Sell
14,019
-6,224
-31% -$468K 0.03% 363
2020
Q4 		$1.36M Buy
20,243
+4,759
+31% +$258K 0.04% 331
2020
Q3 		$797K Hold
15,484
– – 0.03% 370
2020
Q2 		$584K Sell
15,484
-5,646
-27% -$193K 0.02% 369
2020
Q1 		$630K Buy
21,130
+2,375
+13% +$71.7K 0.03% 352
2019
Q4 		$645K Sell
18,755
-18,400
-50% -$450K 0.02% 376
2019
Q3 		$672K Buy
+37,155
New +$824K 0.02% 380

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Chartwell Investment Partners's CSTL Position: Q2 2022 in Review

Chartwell Investment Partners sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 14,508 shares — an estimated $651K sold.

Chartwell Investment Partners first reported a position in CSTL in Q3 2019 and held it in 11 quarters. The position peaked at $1.36M in Q4 2020. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Chartwell Investment Partners reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 14,508 Castle Biosciences shares in Q2 2022, an estimated $651K.
  • Chartwell Investment Partners first reported a position in Castle Biosciences in Q3 2019 and held it in 11 quarters.
  • Chartwell Investment Partners's Castle Biosciences position peaked at $1.36M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Chartwell Investment Partners's 13F filing for Q2 2022, filed 1 Aug 2022.